Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Target ID: TTDS00172

Target Information
NameSerotonin re-uptake    
Type of targetSuccessful target    
SynonymsSerotonin reuptake    
DiseaseAnxiety disorder, unspecified    [1]
Depression    [2]
Dysphoria    [3]
Obesity    [4]
Psychiatric illness    [5]
Social phobias    [6]
Drug(s)(S)-DuloxetineApprovedSmoking cessation[7][8]
AmfepramoneApprovedObesity[9]
AmitriptylineApprovedDepression and chronic pain[10][11]
BupropionApprovedDepression[12]
CitalopramApprovedDepression[13]
ClomipramineApprovedDepression[14]
CocaineApprovedAnesthetic[15]
DexfenfluramineApprovedObesity[16]
DiethylpropionApprovedMigraine and Obisity[17]
DuloxetineApprovedDepression[18][7]
EscitalopramApprovedDepression[19]
FluoxetineApprovedDepression[20][21]
FluvoxamineApprovedDepression[22][23]
Milnacipran HClApprovedFibromyalgia[24]
ParoxetineApprovedDepression[20]
SeroxatApprovedDepression[25][26][27]
SertralineApprovedDepression[13][20]
SibutramineApprovedObesity[28]
TianeptineApprovedDepression[29]
TrazodoneApprovedDepression[12][21]
TrimipramineApprovedDepression[29]
UltracetApprovedPain[25]
VenlafaxineApprovedDepression[12]
Trazodone CRPhase IV completedFibromyalgia, Major Depressive Disorder, Severe Mood Disorders[12]
BicifadinePhase III completedChronic Low Back Pain,Neuropathic pain[30]
Tramadol ERPhase III completedNeuropathic pain, Postherpetic neuralgia[30]
Desvenlafaxine SRPhase IIIDepressive Disorder, Painful diabetic neuropathy[30]
DOV 21947Phase IISevere Mood Disorders[31]
DOV-21947Phase IISevere Mood Disorders[31]
OPC-14523Phase IIBulimia nervosa OCD MDD, Severe Mood Disorders[32]
TGBA01ADPhase IISevere Mood Disorders[31]
OPC-14523Phase IFemale sexual dysfunction[32]
DOV-216303Discontinued in Phase IISevere Mood Disorders[31]
GSK372475Discontinued in Phase IIADHD; Severe Mood Disorders[31]
NS 2359Discontinued in 2009 in phase II Attention-deficit/hyperactivity disorder, depression and cocaine addiction[33]
R-sibutramine metaboliteDiscontinued in Phase IIDepression, Attention Deficit/Hyperactivity Disorder (ADHD)[31]
Related US Patent6,239,129
6,316,469
6,342,498
6,372,763
6,380,200
6,384,281
6,399,608
6,410,736
6,492,366
6,509,340
6,552,014
6,596,741
6,664,274
6,677,338
6,677,378
6,787,560
Target ValidationClick to Find Target Validation Information.    
Inhibitor (S)-Duloxetine[7][8]
Amfepramone[9]
Amitriptyline[10][11]
Bicifadine[30]
Bupropion[12]
Citalopram[13]
Clomipramine[14]
Cocaine[15]
DOV 21947[31]
DOV-216303[31]
DOV-21947[31]
Desvenlafaxine SR[30]
Dexfenfluramine[16]
Diethylpropion[17]
Duloxetine[18][7]
Escitalopram[19]
Fluoxetine[20][21]
Fluvoxamine[22][23]
GSK372475[31]
Hypericum (St John's Wort)[34]
Milnacipran HCl[24]
NS 2359[33]
OPC-14523[32]
Paroxetine[20]
R-sibutramine metabolite[31]
Seroxat[25][26][27]
Sertraline[13][20]
Sibutramine[28]
TGBA01AD[31]
Tianeptine[29]
Tramadol ER[30]
Trazodone[12][21]
Trazodone CR[12]
Trimipramine[29]
Ultracet[25]
Venlafaxine[12]
MultitargetAmfepramone[9]
Amitriptyline[10][11]
Bicifadine[30]
Bupropion[12]
Cocaine[15]
DOV 21947[31]
DOV-216303[31]
DOV-21947[31]
Desvenlafaxine SR[30]
Diethylpropion[17]
Duloxetine[18][7]
GSK372475[31]
Milnacipran HCl[24]
NS 2359[33]
OPC-14523[32]
R-sibutramine metabolite[31]
Sibutramine[28]
TGBA01AD[31]
Tramadol ER[30]
Trazodone[12][21]
Trazodone CR[12]
Trimipramine[29]
Ultracet[25]
Venlafaxine[12]
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1Considerations in the treatment of anxiety disorders: a pharmacoeconomic review. Expert Opin Pharmacother. 2001 Oct;2(10):1557-69. To Reference
Ref 2Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression. S Afr Med J. 1997 Apr;87(4 Suppl):534-7, 540. To Reference
Ref 3SSRIs for premenstrual dysphoric disorder. Drug Ther Bull. 2002 Sep;40(9):70-2. To Reference
Ref 4Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26. To Reference
Ref 5Selective serotonin re-uptake inhibitors for children and adolescents. Eur Child Adolesc Psychiatry. 2000;9 Suppl 1:I20-6. To Reference
Ref 6Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI. Expert Opin Investig Drugs. 2000 Oct;9(10):2215-31. To Reference
Ref 7Duloxetine for the treatment of generalized anxiety disorder: a review. Neuropsychiatr Dis Treat. 2009;5:23-31. Epub 2009 Apr 8. To Reference
Ref 8Electrophysiological characterization of the effect of long-term duloxetine administration on the rat serotonergic and noradrenergic systems. J Pharmacol Exp Ther. 1998 May;285(2):404-12. To Reference
Ref 9Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418. To Reference
Ref 10Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6. To Reference
Ref 11A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):285-90. To Reference
Ref 12Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92. To Reference
Ref 13Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6. Epub 2007 Sep 17. To Reference
Ref 14Efficacy of treatments for patients with obsessive-compulsive disorder: a systematic review. J Am Acad Nurse Pract. 2009 Apr;21(4):207-13. To Reference
Ref 15Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81. Epub 2009 Apr 17. To Reference
Ref 16Serotonergic drugs : effects on appetite expression and use for the treatment of obesity. Drugs. 2007;67(1):27-55. To Reference
Ref 17Phentermine and anaesthesia. Anaesth Intensive Care. 2005 Aug;33(4):525-7. To Reference
Ref 18Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42. Epub 2006 Nov 28. To Reference
Ref 19Antidepressants and sleep: a review. Perspect Psychiatr Care. 2009 Jul;45(3):191-7. To Reference
Ref 20Methadone: from pharmacokinetic profile to clinical pharmacology. Encephale. 2006 Jul-Aug;32(4 Pt 1):478-86. To Reference
Ref 21Curr Top Med Chem. 2006;6(17):1801-23.Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey. To Reference
Ref 22Changes of functional MRI findings in a patient whose pathological gambling improved with fluvoxamine. Yonsei Med J. 2009 Jun 30;50(3):441-4. Epub 2009 Jun 24. To Reference
Ref 23Placebo controlled double-blind trial of fluvoxamine maleate in the obese. J Psychosom Res. 1986;30(2):143-6. To Reference
Ref 24Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. To Reference
Ref 25Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Jun 11. [Epub ahead of print] To Reference
Ref 26A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry. 2001 May;34(3):85-90. To Reference
Ref 27Depression with anxiety and atypical depression. J Clin Psychiatry. 1993 Feb;54 Suppl:10-4; discussion 15. To Reference
Ref 28Sibutramine and the management of obesity. Expert Opin Pharmacother. 2004 Mar;5(3):633-42. To Reference
Ref 29Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39. To Reference
Ref 30Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. To Reference
Ref 31Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. Epub 2008 Jan 2. To Reference
Ref 32Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36. To Reference
Ref 33Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34. To Reference
Ref 34The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.). Mol Psychiatry. 1999 Jul;4(4):333-8. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543